Skyrizi 600 mg/10 ml Injection

Skyrizi 600mg/10ml Injection – Risankizumab IL-23 Inhibitor

Skyrizi (risankizumab) 600 mg/10 mL Injection is a humanised monoclonal antibody that selectively blocks interleukin-23 (IL-23), a signalling protein that drives the inflammation behind plaque psoriasis, psoriatic arthritis and Crohn’s disease. By binding the p19 subunit of IL-23, it interrupts that inflammatory pathway at source. This presentation is a 10 mL single-dose vial at 60 mg/mL for intravenous infusion – it must be diluted before use and given by a healthcare professional, typically as the induction dose in Crohn’s disease. Prescription-only biologic (Rx Only).

Key Features

• Risankizumab 600 mg per 10 mL vial (60 mg/mL)
• Selective IL-23 p19 inhibitor – targeted biologic therapy
• For intravenous use only – must be diluted prior to infusion
• One 10 mL single-dose vial; discard any unused portion
• Clear to slightly yellow, preservative-free solution from AbbVie

Composition

• Risankizumab – 600 mg per 10 mL (60 mg/mL)
• Supplied in a sterile, preservative-free aqueous solution for dilution and intravenous infusion

Uses & Benefits

• Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy
• Active psoriatic arthritis in adults
• Moderately to severely active Crohn’s disease – this IV strength is the induction presentation
• Targets the IL-23 pathway rather than suppressing immunity broadly
• Long dosing intervals – maintenance is typically every 8 to 12 weeks
• Can reduce skin plaques, joint pain and bowel inflammation depending on indication

Directions for Use

• Administered by a healthcare professional only – this is not a self-injection presentation
• Must be diluted before use and given as an intravenous infusion per the prescribing information
• Dose and schedule are set by your specialist based on the indication and body weight
• Inspect the solution before use; do not use if cloudy, discoloured or containing particles
• Single-dose vial – discard any unused portion; do not save for later

Precautions

• Screen for tuberculosis before starting and monitor during treatment; do not start in active TB or any active serious infection
• May increase the risk of infections – report fever, cough, burning on urination or other infection signs promptly
• Live vaccines should be avoided during treatment; complete required immunisations beforehand
• Serious hypersensitivity reactions can occur – seek urgent care for rash, swelling or breathing difficulty
• Tell your doctor if you are pregnant, planning pregnancy or breastfeeding
• Liver enzyme changes have been reported – your doctor may check blood tests during therapy

Storage

• Refrigerate at 2°C to 8°C in the original carton to protect from light
• Do not freeze and do not shake; keep the cold chain intact at all times
• Keep out of reach of children

Disclaimer

Prescription-only biologic medicine. To be prescribed, dispensed and administered only under the supervision of a qualified specialist in an appropriate clinical setting. This information is for general awareness and is not a substitute for professional medical advice, diagnosis or treatment, nor for the official prescribing information supplied with the product.